VAL-083 is a structurally unique, "first-in-class", small-molecule chemotherapeutic.
Recruiting
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE): More InformationActive, not recruiting
The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of
For Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma: More InformationActive, not recruiting
The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the
For Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression: More InformationWithdrawn
This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer (REPROVe): More InformationThe purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and
For Patients With Recurrent Malignant Glioma: More Information
VAL-083 demonstrates activity in a wide range of cancer cell lines, including pediatric and adult GBM cell lines and GBM cancer stem cells.
